Immutep Ltd. IMMP 深 滬
已收盤 09-26 16:00:00 美东时间
1.72
+0.040
+2.38%
華盛通- 最 高1.75
- 今 開1.665
- 成交量 9.76万股
- 最 低 1.665
- 昨 收 1.68
- 總市值 2.53亿
- 52周最高 2.71
- 市盈率 靜 --
- 換手率 0.07%
- 52周最低 1.32
- 委 比 -20.68%
- 總股本 1.47亿
- 歷史最高 7.95
- 量 比 0.84
- 振 幅 5.06%
- 歷史最低 0.53
- 每 手 1
- 風險率 0.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti
Immutep Limited has initiated a Phase II trial evaluating neoadjuvant eftilagimod alfa (efti) as monotherapy and in combination with chemotherapy in HR+/HER2-negative breast cancer patients. The study, led by GW Cancer Center, aims to assess pathological complete response rates and will enroll up to 50 patients. Efti, a novel immunotherapy, activates a broad anti-cancer immune response and has shown promise in earlier-stage disease. Immutep provi...
09-22 12:00
Immutep Collaborates with GW Cancer Center on Efti Trial for Breast Cancer
The latest announcement is out from Immutep Ltd ( ($AU:IMM) ). Immutep Limited ...
09-22 07:47
KAT6 Inhibitors Market Poised for Significant Growth During the Forecast Period (2025-2040) | DelveInsight
The outlook for the KAT6 inhibitors market is strengthening as interest in epig...
09-17 05:31
Immutep To Present Phase II EFTISARC-NEO Trial Data On Efti + KEYTRUDA Combo In Soft Tissue Sarcoma At CTOS 2025
Data to be presented in the Immunotherapy & Cell Therapy in Sarcoma: Emerging Frontiers session at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting SYDNEY, AUSTRALIA, Sept. 08, 2025 (GLOBE
09-08 20:12
Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025
Immutep Limited announces that an abstract for the EFTISARC-NEO Phase II trial has been accepted for oral presentation at the CTOS 2025 Annual Meeting. The trial evaluates eftilagimod alpha (efti) in combination with pembrolizumab and radiotherapy for patients with soft tissue sarcoma (STS). STS is a rare cancer with high unmet medical needs; in the US, approximately 13,520 new cases and 5,420 deaths are expected in 2025. The presentation will hi...
09-08 12:00
Immutep Reports Increased Losses Amid Rising R&D Costs
Immutep ( ($IMMP) ) just unveiled an announcement. Immutep Limited reported its...
09-03 18:40
Immutep Gains FDA Support for Cancer Therapy Development
Immutep Ltd ( ($AU:IMM) ) has shared an announcement. Immutep Limited has recei...
08-05 09:08
Immutep Advances Oncology Trials with Promising Results
The latest update is out from Immutep Ltd ( ($AU:IMM) ). Immutep Limited has re...
07-30 07:18
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer
Immutep Limited will present a poster on its pivotal TACTI-004 Phase III trial at the 2025 World Conference on Lung Cancer in Barcelona. The trial evaluates eftilagimod alfa (efti) combined with pembrolizumab and chemotherapy for first-line treatment of advanced or metastatic non-small cell lung cancer (NSCLC). The global trial will enroll approximately 750 patients across 150 sites in over 25 countries. The presentation will highlight the study ...
07-29 12:00
Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
Immutep Limited, a late-stage immunotherapy company, announces that three abstracts for clinical trials evaluating its MHC Class II agonist eftilagimod alfa (efti) have been accepted for presentation at the ESMO Congress 2025 in Berlin. The presentations include a Proffered Paper on the EFTISARC-NEO trial in soft tissue sarcoma, a poster on the INSIGHT-003 trial in non-small cell lung cancer (NSCLC), and an ePoster on the pivotal TACTI-004 Phase ...
07-28 12:00
